Fate Therapeutics Inc. Stock
Fate Therapeutics Inc. Stock
Pros and Cons of Fate Therapeutics Inc. in the next few years
Pros
Cons
Performance of Fate Therapeutics Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Fate Therapeutics Inc. | -1.880% | -14.595% | -26.874% | -16.608% | 33.296% | -93.009% | - |
| Ardelyx Inc. | -0.620% | -12.086% | -15.475% | 35.391% | 4.706% | -16.524% | - |
| Salarius Pharmaceuticals Inc. | 1.850% | 10.553% | -19.266% | -71.613% | -20.721% | -98.176% | -99.994% |
| Evolus Inc | -1.830% | -7.627% | -15.504% | 39.744% | 16.578% | 15.344% | - |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Upon initial examination, the financial statements of Fate Therapeutics, a biotechnology and medical research company trading under the ticker symbol FATE, appear to showcase a company experiencing ongoing losses in recent periods. However, a deeper analysis is required to fully understand the company's financial performance and identify any potential pros and cons.
Growing Revenue: For three consecutive years from 2020 to 2022, FATE's total revenue has showcased a continuous growth trend, with a significant increase of approximately 308% from 2020 to 2022. This increase might suggest that the company's products and pipelines are gaining traction in the market.
Solid Net Working Capital: Throughout the analyzed periods, FATE has maintained a healthy net working capital position, generally showcasing a larger number of current assets than current liabilities. This indicates that the company is well-positioned to cover its short-term obligations.
Comments